Furthermore, since PCMT1 overexpression could reduce the infiltration of tumor-killing immune cells, therapies aimed at reducing PCMT1 levels may oppose cancer immunoediting and enhance host antitumor response (Fig. 7). This evidence concerns the gene PCMT1 and cancer.